Montelukast dicyclohexylamine is a salt form of montelukast, a potent and selective antagonist of the cysteinyl leukotriene receptor 1 (CysLT1). It is formed by combining the active pharmaceutical ingredient montelukast with dicyclohexylamine. This specific salt form is primarily utilized as a key intermediate in the synthesis and purification of montelukast sodium, the final marketed drug substance. The primary application of this compound is in the pharmaceutical manufacturing process for montelukast, a widely prescribed medication for the prophylaxis and chronic treatment of asthma and for the relief of symptoms of allergic rhinitis. The dicyclohexylamine salt form offers advantages in terms of crystallization, purification, and handling during the production of the final active pharmaceutical ingredient (API). As an intermediate, it is a critical chiral building block, ensuring the stereochemical integrity of the final drug product. Its use is confined to controlled industrial synthesis processes and it is not intended for direct therapeutic use.